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Abstract
Background: Osteoporosis is a growing worldwide problem, with the greatest burden resulting from fractures.
Nevertheless, the majority of fractures in adults occur in those with “osteopenia” (bone mineral density (BMD) only
moderately lower than young normal individuals). Since long-term drug therapy is an expensive option with
uncertain consequences and side effects, natural herbal therapy offers an attractive alternative. The purpose of this
study is to evaluate the effect on BMD and safety of the Classic Yin and Yang Tonic Formula for treatment of
osteopenia and to investigate the mechanism by which this efficacy is achieved.
Methods/design: We propose a multicenter double-blind randomized placebo-controlled trial to evaluate the
efficacy and safety of the Classic Yin and Yang Tonic Formula for the treatment of osteopenia. Participants aged 55
to 75 with low bone mineral density (T-score between -1 and -2.5) and kidney deficiency in TCM will be included
and randomly allocated into two groups: treatment group and control group. Participants in the treatment group
will be treated with Classic Yin and Yang Tonic Granule, while the controlled group will receive placebo. Primary
outcome measure will be BMD of the lumbar spine and proximal femur using dual-energy X-ray absorptiometry.
Secondary outcomes will include pain intensity measured with visual analogue scales, quality of life, serum markers
of bone metabolism, indices of Neuro-endocrino-immune network and safety.
Discussion: If the Classic Yin and Yang Tonic Formula can increase bone mass without adverse effects, it may be a
novel strategy for the treatment of osteoporosis. Furthermore, the mechanism of the Chinese medical formula for
osteoporosis will be partially elucidated.
Trial registration: This study is registered at ClinicalTrials.gov, NCT01271647.
Background
Osteoporosis is a growing problem worldwide, with the
greatest burden resulting from fractures. Nevertheless,
the majority of fractures in adults occur in those with
“osteopenia” (bone mineral density (BMD) only moder-
ately lower than young normal individuals). Thus, there
has been an interest in developing approaches to prevent
bone loss. The agents currently approved for treatment
and/or prevention of osteopenia include bisphospho-
nates, hormone replacement therapy with estrogen or
combination estrogen/progesterone preparations, calcito-
nin, raloxifene, and parathyroid hormone as well. But
short- and long-term consequences (adverse effects) of
these therapies continue to be discovered. The adverse
outcomes include cancer, and cardiac, dermatologic, gas-
trointestinal, gynecologic, immunologic, metabolic, mus-
culoskeletal, neurological, psychiatric, and respiratory
events.
Since long-term drug therapy is an expensive option
with uncertain consequences and side effects, natural
h e r b a lt h e r a p yo f f e r sap o s s i b l ea l t e r n a t i v e .T h eC l a s s i c
Yin and Yang Tonic Formula (CYYTF) have been used to
treat osteoporosis or osteopenia in traditional Chinese
medicine (TCM) for a long time. Several putative mechan-
isms for this have been proposed. These include stimula-
tion of osteoblast proliferation and differentiation,
osteogenesis, and inhibition of bone resorption, as a estro-
gen-like function. For this reason, Chinese guidelines for
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However, there is currently no randomized placebo-
controlled trial to verify its efficacy in treating bone mass
loss. The present study is to examine effects of a Chinese
herbal intervention using the Classic Yin and Yang Tonic
Formula (CYYTF) to improve bone mineral density of
patients with osteopenia in a randomized, double-blind,
placebo-controlled trial. Results of this study will provide
evidence regarding the value of the Classic Yin and Yang
Tonic Formula (CYYTF) as an intervention to increase
BMD of osteopenic individuals. Furthermore, the mechan-
isms of action can be partially identified by this study.
Methods and Design
Study Design
This clinical trial is a multi-center, randomized, double-
blind, placebo-controlled design. Subjects will be enrolled
at four hospitals: 1) Longhua hospital affiliated with
Shanghai university of TCM; 2) Huadong hospital
affiliated with Fudan university; 3) The central hospital of
Yangpu district, Shanghai; 4) The Red Cross hopital of
Xi’an. This study is conducted in 4 sites in China.
Ethics Issue
This study has been approved by the Ethics Board of
Shanghai University of TCM (No: 2011LCSY002). Each
participating centre obtained a local Institutional Review
Board Approval. All study participants will sign the written
informed consent prior to participation.
Patients Population and Recruitment Procedure
The study population consists of individuals aged 55 to
75 with BMD below 80% of the young adult mean (YAM)
(T score -1.0 to -2.5 at the lumbar spine or hip). Data for
the YAM and T score values were obtained from reference
data of healthy women 20 to 29 years of age [1]. The indi-
viduals whose syndrome differentiation are kidney defi-
ciency will be included. In traditional Chinese medicine
(TCM), kidney deficiency syndrome is a general term for
deficiency conditions of kidney and Neuro-endocrino-
immune network, The symptoms mainly include: low
back pain, soreness and weakness of the lumbar regions
and knees, dizziness, fatigue, spontaneous sweating, a hot
or cold sensation in the palms, soles and chest, dysphoria,
insomnia, The pulse is weak, the tongue is red and cov-
ered without fur or bulky, moist, and covered with white
fur.
Subjects will be excluded if they have disorders such as
primary hyperparathyroidism; Cushing’s syndrome; pre-
mature menopause due to hypothalamic, pituitary, or
gonadal insufficiency; poorly controlled diabetes mellitus
(HbA1c>8.0%); or other causes of secondary osteoporosis.
Subjects will also be excluded if they have taken bispho-
sphonates at any time. The trial will exclude individuals
who have taken glucocorticoids, calcitonin, vitamin K,
active vitamin D compounds, or hormone replacement
therapy within the previous 2 months. In addition, serum
calcium (Ca) levels above 10.6 mg/dL (2.7 mmol/L) or
below 8.0 mg/dl (2.0 mmol/L), serum creatinine levels
above1.5 mg/dL (133 μmol/L), or clinically significant
hepatic disorders, are also exclusion. Furthermore, subjects
that have Malignancies, or physical or mental disabilities
will be excluded, as well as lactating or pregnant patients.
This study is to be conducted in accordance with
protection of patients, as outlined in the Declaration of
Helsinki, and approved by the appropriate Institutional
Review Boards. Each participant will sign the written
informed consent before undergoing any examination or
study procedure, in compliance with Good Clinical Prac-
tice. We will utilize EpicCare databases to identify all
persons aged 55-75 who had a DXA scan during the prior
two years at any of the four hospitals, and with BMD of
the hip (femoral neck or trochanter) and/or spine falling
within the T-score range of -1.0 and -2.5. The patients
whose syndrome differentiation of TCM is kidney defi-
ciency are included. Patients who initially meet these elig-
ibility criteria are then to complete the additional baseline
testing and will be randomized into either the treatment
or the control group.
Interventions
Eligible patients will be randomized to one of the two
arms: placebo and Chinese medical herb (18 g twice
daily). All drugs will be administered orally for 6 months.
In this study, the treating physicians, subjects, investiga-
tors and statisticians will be blinded to treatment assign-
ment. In this respect, the trial is double-blind.
Randomization of subjects will occur centrally using a
random number generator and will be stratified by syn-
drome differentiation of TCM (Syndrome, as related to
illnesses in Western medicine, is composed of a set of
signs and/or symptoms classified by Traditional Chinese
Medicine practitioners [2]. TCM Syndrome differentia-
tion is based on symptoms and helps to identify a subset
of disease). Patients visit the doctor at 6 and 12 months
follow-up.
Randomization and Allocation
Treatment allocation occurs when the study participant
meets the inclusion criteria and signs the informed con-
sent form. The teletherapist will then register the partici-
pant into the database, which in turn asks if they are
ready to be randomized. After the teletherapist enters
yes, the site-specific randomization program behind the
form displays the participant’s group assignment number
(placebo versus Chinese medical herb). Figure 1 shows
the process of patient enrollment and allocation. Study
participants will be randomized in blocks of random sizes
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will be computer-generated (i.e., generated by an indivi-
dualized basic visual code program) and concealed from
the researchers by a senior data manager who is not
involved in the study. This information will remain confi-
dential and is not shared with the study sites, in concor-
dance with the CONSORT guidelines. This trial uses a
prospective, randomized, outcome-blinded design, in
which all outcome assessments are made by a research
assistant blinded to treatment allocation and uninvolved
in patient consent and management.
Outcome Measurements
The primary outcome of the study is bone mineral den-
sity at 6 and 12 months after treatment with the study
medication. Secondary outcomes include pain intensity,
quality of life, relative changes in bone turnover markers,
neuro-endocrino-immune indices, and safety.
Assessment of bone mineral density (BMD)
Lumbar spine BMD (L1-4) and femoral BMD will be mea-
sured at three measurement points (baseline and 6 and 12
months after the treatment), using the dual energy X-ray
absorptiometry densitometer obtained from Hologic, Inc.
USA. The accuracy of the measurements recorded by the
dual energy X-ray absorptiometry (DXA) instruments is to
be evaluated by the use of serial measurements of a local
spine “phantom”. The variability of DXA measurements
across the different participant centres will also be
assessed via utilization of the same spine “phantom” tech-
nique. Using this technique, the long-term coefficient of
variation of each instrument in the study is estimated as
less than 1%. These “phantom” measurements will be used
to adjust for any “drift” in measurements of bone densito-
metry during the study.
Assessment of bone turnover
Serum samples will be collected at baseline and 6 months
after the treatment for measurement of bone turnover
markers, including type I collagen N-telopeptide (NTX),
serum bone-specific alkaline phosphatase (BALP), serum
osteocalcin (OC), serum Procollagen type I N-terminal
propeptide (PINP), carboxy-terminal telopeptide of type-I
collagen (CTX), and Serum procollagen I carboxy-term-
inal propeptide (PICP).
Health-related quality of life
The ECOS-16 questionnaire is developed with the aim
of measuring health related quality of life (HRQoL) in
postmenopausal women with osteoporosis. It is based
on the combination of two disease-specific HRQoL
questionnaires for women with osteoporosis: the Osteo-
porosis Quality of Life Questionnaire (OQLQ) [3] and
the Quality of Life Questionnaire of the European Foun-
dation for Osteoporosis (QUALEFFO) [4]. The 16 items
in the new questionnaire are divided qualitatively into
four dimensions. The nature of the four dimensions also
suggests that they can be further combined to produce
two summary scores that would include Physical Func-
tion and Pain in one Physical score and another that
would include Fear of Illness and Psychosocial Function
in a Mental score. These two summary scores could, in
t u r n ,b ec o m b i n e dt op r o v i d ea no v e r a l ls c o r ef o rt h e
questionnaire. However, although the 16 items can be
classified qualitatively into four dimensions, this is a
unidimensional questionnaire, according to quantitative
analysis [5]. The score of each item ranges from 1 to 5.
The ECOS-16 questionnaire generates a single summary
score obtained from the arithmetic mean of the
answered items, so the total score ranges from 1 (best
HRQoL) to 5 (worst HRQoL). This questionnaire will be
completed at all the measurement points (baseline and 6
and 12 months after the treatment).
Assessment of pain
The Visual Analogue Scale ( V A S )m e a s u r e sa m o u n to f
pain, which is a pain score ranging from 0 (no pain) to
100 (worst pain ever) [6]. Operationally, the VAS score is
usually a horizontal line, 100 mm in length, anchored by
word descriptors at each end. The patient marks on the
line the point that they feel represents their perception of
their current pain. The VAS score is then determined by
measuring in millimetres from the left hand end of the
line to the point that the patient marks. The VAS score
will be measured at all the measurement points (baseline
and 6 and 12 months after the treatment).
Potential participants identified via databases of four hospitals
Patients are interviewed by phone for interest and eligibility
In-person interview for eligibility
consent
Screening and baseline DEXA
randomization
Treatment group Control group
6 months  outcome assessment
12 months outcome assessment
Figure 1 The flow diagram of this study, including eligibility,
screening, randomization and outcome assessment.
Yang et al. Trials 2011, 12:187
http://www.trialsjournal.com/content/12/1/187
Page 3 of 5Assessment of adverse events
All subjects are to be questioned about adverse events
(AEs) during treatment at each visit point, and all adverse
events reported will be analyzed regardless of the investi-
gators’ assessments of causality. The Medical Dictionary
for Regulatory Activities (MedDRA, Version 8.1J) will be
used to categorize reported adverse events.
Sample Size Considerations
We calculate the required sample size for this trial based
on the following calculation: n = 2s
2 ×f ( a,b)/(μ1-μ2)
2 [7].
First, we estimate that an absolute improvement of 7.8%
(from μ1 to μ2, μ1 = 0.803, μ2 = 0.866) in BMD was likely
the smallest clinically-relevant difference [8]. Second, we
assume that standard deviation of BMD may be 0.125 (s =
0.125) at baseline[9]. Based on these assumptions, we will
require 84 patients in each group to have at least a 90%
power b = 0.1 and to rule out a two-sided type I error of
5% a = 0.05. This number of patients actually provides
less than 80% power, assuming an withdrawal rate of 20%.
Therefore, we will recruit approximately a total of 204
patients, 102 patients in each group.
Statistical Analysis
The data will be collected and analysed according to the
intention-to-treat principle. Standard statistical techniques
will be used to describe characteristics of patients in both
groups. We will compare baseline characteristics in both
groups and if incomparability appears, we will perform the
secondary analysis, adjusting for differences. The primary
outcome, BMD, will be compared between both groups
using analysis of variance for repeated measures. If adjust-
ment for possible baseline incomparability is needed, ana-
lysis of covariance will be done.
Discussion
Osteoporosis is a major cause of morbidity and mortality
in older persons. For individuals identified to be at risk for
developing osteoporosis, intervention measurements are
aimed at preventing the condition from getting worse,
whereas in those who have already presented with low
BMD or fractures, treatment is aimed at preventing
further bone loss to reduce the risk of initial or subsequent
fracture. Currently, there is no good evidence that these
BMD differences may then translate in fracture reduction
changes. However, Low bone mineral density (BMD) is a
known risk factor of fracture and a strong predictor of
new vertebral fracture [10,11]. A previous publication
reported that after the adjustment for age and BMI, the
odds of having a vertebral fracture in Southern Chinese
women was 2.3(1.6-3.3) for each 1 SD reduction in spine
BMD and 2.1(1.37-3.20) for femoral neck BMD [12]. A
latest publication revealed that women with prevalent ver-
tebral fractures had significantly lower BMD than those
without prevalent vertebral fractures[13]. Therefore, we
use BMD as the primary outcome.
Estrogens have important anticatabolic and anabolic
effects on bone, and estrogen deficiency plays a central
role in the development of osteoporosis [14]. Hormone
replacement therapy (HRT) effectively prevents bone loss
in postmenopausal women [15,16] and reduces the inci-
dence of fractures[17,18]. However, long-term acceptance
or compliance of HRT is generally poor in postmenopau-
sal due to the potential complications, such as uterus
hyperplasia and breast cancer [19,20]. A recent review
suggested that many non-leguminous plants are rich in
phytoestrogen, which is regarded as a prospective candi-
date for treatment of postmenopausal osteoporosis [21].
Among non-leguminous plants, Epimedium brevicornum
maxim is a centuries-old medicinal herb. It is reputed by
Traditional Chinese Medicine to have “bone strengthen-
ing” f u n c t i o na n du s e df o rt r e a tment of musculoskeletal
disorders [22]. Epimedium-derived phytoestrogen flavo-
noids (EPFs) have been shown to prevent bone loss in
late postmenopausal women, as indicated by the signifi-
cant maintenance of BMD in the EPF treatment group
compared to the placebo control group [23]. In this
study, the Classic Yin and Yang Tonic Formula contains
diverse phytoestrogen, such as isoflavone, lignans and
coumarin. If this study demonstrates the effectiveness
and safety of the Classic Yin and Yang Tonic Formula
significant strides would be made towards a clinically
useful therapy for reducing bone mass loss.
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